Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Significant one-time order for Nexstim

NXTMHAnalyst Comment12.06.2026 klo 09.28
Antti SiltanenAnalyst
Discuss

Summary

  • Nexstim announced a significant order for ten NBS 6 systems from a distributor, likely Brainlab, to be delivered in the US and Europe during the current year's first and second halves.
  • This order is the largest in Nexstim's history and aligns with expectations for larger one-time orders through distributors, indicating a growth trajectory in this sales channel.
  • The order supports growth estimates for the current year, with Nexstim's full-year 2026 revenue expected to grow by nearly 16% to 12.7 MEUR, driven by double-digit growth in equipment sales.
  • Despite a quiet start to the year with only three systems delivered in Q1, the order aligns with anticipated sales growth towards the year's end, supported by Brainlab's sales resources.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 06/12/2026 at 08:11 am EEST

Nexstim announced on Thursday that it had received an order for ten NBS 6 systems from its distributor. The systems will be delivered to the US and Europe during the first and second halves of the current year. The release instills confidence in our growth estimates for this year.

A large one-off order from a distributor refers to Brainlab

According to the release, the ordered systems include both diagnostic and therapy features. Although Nexstim did not name the distributor in the press release, we consider it likely to be the company's strategic partner, Brainlab. Last year, Nexstim announced numerous individual system deliveries between May and August. This year, it appears that a similar order intake has materialized as the single largest order in Nexstim's history. We also expect future deals through distributors to materialize as larger one-time orders compared to before. Prior to this, Nexstim had already reported three systems sold through distributors this year, so this sales channel appears to be on a clear growth trajectory. This is in line with our expectations, as Nexstim has stated that the Brainlab collaboration will begin to yield results more fully from 2026–27 onwards. 

Important support for this year's growth estimates

Nexstim's early year was seasonally quiet in terms of system deliveries, as the company delivered three systems in Q1. We have been expecting system sales to pick up clearly towards the end of the year, supported by Brainlab's sales resources. The now announced order for ten systems is large by Nexstim's standards (2025:   37 deliveries), and it is in line with the development we estimate. We expect the company's full-year 2026 revenue to grow by just under 16% to 12.7 MEUR, which will largely rely on double-digit growth in equipment sales. As the order's deliveries are scheduled for both H1 and H2, we believe it supports our full-year estimates.

 

Login required

This content is only available for logged in users

Create account

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more on company page

Key Estimate Figures14.05.

202526e27e
Revenue11.012.716.1
growth-%25.5 %15.7 %26.8 %
EBIT (adj.)0.61.22.3
EBIT-% (adj.)5.8 %9.5 %14.1 %
EPS (adj.)0.080.120.27
Dividend0.000.000.00
Dividend %
P/E (adj.)123.386.540.2
EV/EBITDA43.034.422.4

Forum discussions

Through Brainlab, sales are certainly weighted toward the end of the year, as the seasonal fluctuation is driven precisely by customers and ...
yesterday
by Kyhnykeisari
24
For the past year or two, it has been said that Brainlab’s impact on sales will become prominent for the first time in late 2026… properly. ...
yesterday
by Taitoo
9
Inderes predicted 52 systems for the whole year. Now we are 12 systems away from that, and the last quarter hasn’t even started yet. And now...
yesterday
by Matti Kukkaro
26
Aren’t we already in the neighborhood of Inderes’ estimates, or at least not behind by many machines. It’s hard to imagine that a sharp drop...
yesterday
by QRB Strong buy
7
Nexstim’s sales have previously been heavily weighted toward the end of the year, which has been explained by the procurement patterns of hospitals...
yesterday
by Tojopa
8
The momentum is really great, I can’t remember even around Christmas time previously having trades four days in a row.
yesterday
by ghoul
20
The unsuccessful Aiforia was removed from the model portfolio. Nexstim would offer a good playing field for the model portfolio. The stock has...
yesterday
by Umpi
31